Twist Bioscience (NASDAQ:TWST) Price Target Raised to $50.00

Twist Bioscience (NASDAQ:TWST) had its price target boosted by Evercore ISI from $46.00 to $50.00 in a report issued on Friday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

Several other brokerages also recently issued reports on TWST. Robert W. Baird lifted their price objective on Twist Bioscience from $39.00 to $40.00 and gave the stock an outperform rating in a research report on Friday. Barclays increased their price objective on Twist Bioscience from $40.00 to $45.00 and gave the company an overweight rating in a research note on Friday. Scotiabank upped their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a sector outperform rating in a report on Monday, February 5th. Finally, The Goldman Sachs Group upgraded shares of Twist Bioscience from a neutral rating to a buy rating and lifted their price target for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of Buy and an average target price of $41.67.

Twist Bioscience Stock Performance

TWST opened at $41.60 on Friday. The stock’s 50 day simple moving average is $34.03 and its 200 day simple moving average is $31.14. Twist Bioscience has a 1-year low of $11.81 and a 1-year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. During the same quarter in the previous year, the company posted ($1.06) EPS. The business’s revenue was up 25.1% on a year-over-year basis. On average, equities analysts expect that Twist Bioscience will post -3.17 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $55,658.41. Following the sale, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the transaction, the chief executive officer now directly owns 516,409 shares in the company, valued at approximately $19,329,188.87. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert Chess sold 4,110 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the sale, the director now directly owns 64,169 shares in the company, valued at $2,244,631.62. The disclosure for this sale can be found here. Insiders have sold 13,211 shares of company stock worth $449,573 in the last quarter. 3.92% of the stock is owned by corporate insiders.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Twist Bioscience by 23.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,617 shares of the company’s stock worth $316,000 after purchasing an additional 2,933 shares during the period. Strs Ohio boosted its stake in Twist Bioscience by 6.5% in the third quarter. Strs Ohio now owns 27,900 shares of the company’s stock valued at $565,000 after acquiring an additional 1,700 shares during the period. Rockland Trust Co. grew its holdings in shares of Twist Bioscience by 29.7% during the third quarter. Rockland Trust Co. now owns 38,500 shares of the company’s stock valued at $780,000 after purchasing an additional 8,808 shares during the last quarter. TD Asset Management Inc raised its position in shares of Twist Bioscience by 137.7% during the 3rd quarter. TD Asset Management Inc now owns 73,148 shares of the company’s stock worth $1,482,000 after purchasing an additional 42,374 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in Twist Bioscience by 51.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after purchasing an additional 1,179 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.